Cellanome commercialized the R3200 platform that integrates live‑cell imaging, AI segmentation, micro‑3D printing and sequencing to link phenotypes to transcriptomes in longitudinal experiments, the company demonstrated at AGBT. Cellanome’s CellCage technology creates customizable microenclosures that keep cells viable while allowing diffusion of reagents for multi‑timepoint assays. Company CSO Gary Schroth (ex‑Illumina) highlighted the system’s ability to study cell–cell interactions and adherent cells in their native states, reporting flow‑cell configurations that can generate up to 10,000 CellCage enclosures per lane—positioning the technology for functional screening and phenotypic discovery workflows.